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ﬁbrosis characterize the pathological features of Schistosoma
mansoni infection. Based on previously observed substantial
anti-ﬁbrotic effects of 24-nor-ursodeoxycholic acid (norUDCA)
in Abcb4/Mdr2/ mice with cholestatic liver injury and biliary
ﬁbrosis, we hypothesized that norUDCA improves inﬂamma-
tion-driven liver ﬁbrosis in S. mansoni infection.
Methods: Adult NMRI mice were infected with 50 S. mansoni
cercariae and after 12 weeks received either norUDCA- or ursode-
oxycholic acid (UDCA)-enriched diet (0.5% wt/wt) for 4 weeks.
Bile acid effects on liver histology, serum biochemistry, key
regulatory cytokines, hepatic hydroxyproline content as well as
granuloma formation were compared to naive mice and infected
controls. In addition, effects of norUDCA on primary T-cell activa-
tion/proliferation and maturation of the antigen-presenting-cells
(dendritic cells, macrophages) were determined in vitro.
Results: UDCA as well as norUDCA attenuated the inﬂammatory
response in livers of S. mansoni infected mice, but exclusively
norUDCA changed cellular composition and reduced size of hepa-
tic granulomas as well as TH2-mediated hepatic ﬁbrosis in vivo.
Moreover, norUDCA affected surface expression level of major
histocompatibility complex (MHC) class II of macrophages andJournal of Hepatology 20
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M-CSF, macrophage colony-stimulating factor.cytes in vitro, whereas UDCA had no effect.
Conclusions: This study demonstrates pronounced anti-inﬂam-
matory and anti-ﬁbrotic effects of norUDCA compared to UDCA
in S. mansoni induced liver injury, and indicates that norUDCA
directly represses antigen presentation of antigen presenting
cells and subsequent T-cell activation in vitro. Therefore, nor-
UDCA represents a promising drug for the treatment of this
important cause of liver ﬁbrosis.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY license.Introduction
Liver ﬁbrosis represents an overwhelming wound-healing
process, characterized by excessive deposition of extracellular
matrix, to chronic injury which is frequently driven by inﬂamma-
tion [1,2]. Soluble factors produced by invading inﬂammatory
cells such as proinﬂammatory and proﬁbrogenetic cytokines and
chemokines play a pivotal role in the activation and transforma-
tion process of hepatic stellate cells as major cellular source for
extracellular matrix production within the injured liver [3]. Schis-
tosoma mansoni (S. mansoni) infection demonstrates a leading
cause for liver ﬁbrosis, portal hypertension and its sequels include
variceal bleeding and ascites [4]. Portal hypertension in S. mansoni
infected individuals results from increased hepatic resistance to
blood ﬂow primarily related to a sustained inﬂammatory-driven
ﬁbrotic process as a consequence of egg-induced granuloma
formation [5]. Although antihelminthic therapy is effective to
treat S. mansoni infection in many patients, portal hypertension
and its complications may persist, reﬂecting the urgent need for
novel treatment strategies for S. mansoni induced liver ﬁbrosis.
Recently, several novel bile acid derivatives, including side
chain-shortened bile acids such as 24-nor-ursodeoxycholic acid15 vol. 62 j 871–878
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Fig. 1. NorUDCA ameliorates liver histology of chronically Schistosoma
mansoni infected NMRI mice. (A) Representative liver histology images (HE;
original magniﬁcation 100), of female NMRI mice, 16 weeks after infection with
50 S. mansoni cercariae, receiving control diet and UDCA (0.5% wt/wt) or norUDCA
(0.5% wt/wt) enriched diet for 4 weeks, are shown (original magniﬁcation 100).
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(norUDCA) [6], were identiﬁed as promising new treatment
options for common and important diseases such as arterioscle-
rosis, metabolic syndrome, and liver ﬁbrosis [7–9], which has fos-
tered a rebirth of bile acid research [10,11]. Data obtained in
Abcb4/Mdr2/ (canalicular phospholipid export pump/multidrug
resistance protein 2) mice, representing a well characterized
model system for sclerosing cholangitis and biliary type of liver
ﬁbrosis, suggest potential direct anti-inﬂammatory and anti-
ﬁbrotic effects of norUDCA [6,12,13]. However, since Abcb4/
mice suffer from defective bile formation (i.e., the lack of biliary
phospholipid secretion with consecutive toxic bile formation)
and norUDCA also has substantial effects on bile formation and
composition [14,15], it remains unclear whether this promising
compound is able to exert beneﬁcial mechanisms in non-chole-
static types of liver ﬁbrosis. S. mansoni related pathology is
mainly induced by cellular immune responses and orchestrated
by CD4-positive T-lymphocytes [16,17]. TH1 dominates the early
inﬂammatory infectious reaction, which shifts towards an egg-
driven TH2-reaction later on. Based on the ﬁndings of these lon-
gitudinal studies, it is suggested that an imbalanced TH1/TH2-
response may represent a pivotal trigger for S. mansoni induced
liver ﬁbrosis [18,19]. However, the therapeutic potency of novel
bile acid analogues such as norUDCA in counteracting the inﬂam-
matory and/or ﬁbrotic response in a murine model of hepatic
schistosomiasis has not been explored so far.
Therefore, the aim of this study was to explore the therapeutic
efﬁcacy of norUDCA in vivo, in a mouse model of S. mansoni
induced liver ﬁbrosis, compared to the effectiveness of its mother
compound UDCA.In addition, a naive (uninfected) group was studied. (B) Infection with 50 S.
mansoni cercariae resulted in uniformly infection levels in all infected groups,
conﬁrmed by antibody detection directed against parasite eggs. (C) Morphomet-
ric analysis of granuloma diameter revealed a signiﬁcant reduction of granuloma
size after norUDCA treatment compared to control and UDCA group. ⁄p <0.05 (vs.
naive), #p <0.05 (vs. control), p <0.05 (vs. UDCA).Materials and methods
S. mansoni mouse model and infection
Six- to eight-week-old NMRI mice (Charles River Laboratories, Germany) were
housed in an animal facility with a 12:12 h light/dark cycle, with ad libitum water
and free access to standard chow (SSNIFF, Soest, Netherlands). The experimental
protocols were performed according to the German animal protection law and
approved by the local animal care and use committee. Schistosomal cercariae
were generated in a Brazilian S. mansoni strain held in a cycle with NMRI mice
and Biomphalaria glabrata (B. glabrata) water snails (Puerto Rico) [20]. S. mansoni
cercariae were obtained by mass shedding of 5–10 infected B. glabrata after light
exposure. Mice were exposed to parasites for 90 min by sitting in a water bath
enriched with approximately 50 S. mansoni cercariae. Infection grade was esti-
mated by determination of hepatic granuloma count in hematoxylin/eosin-
stained liver slices using a conventional microscope (magniﬁcation 100).
Bile acid treatment
Twelve weeks following S. mansoni infection, a time point when liver ﬁbrosis is
already fully established, mice were fed either standard chow (control, n = 7),
0.5% (wt/wt) norUDCA-supplemented diet (norUDCA, n = 14) or 0.5% (wt/wt)
UDCA-supplemented diet (UDCA, n = 12) for four weeks. In addition, naive mice
(naive, n = 7) on standard chow were studied. Thereafter, mice were euthanized
and liver samples and sera were processed as described previously in detail [21].
Serum analysis
Enzymatic assays for detection of serum alanine aminotransferase (ALT), alkaline
phosphatase (AP) and total serum bile acid levels were performed and analyzed
using a cobas 6000 analyzer (Roche Diagnostics, Mannheim, Germany).
Liver histology and hepatic hydroxyproline measurement
One part of the right lobe of each liver (lobe 3) was ﬁxed in 4% neutral buffered
formaldehyde solution and embedded in parafﬁn. Four-lm thin sections were872 Journal of Hepatology 201stained with hematoxylin/eosin (H&E) and Sirius Red (SR) for detection of colla-
gen ﬁbers. Morphometric analysis of granuloma size was performed using ImageJ
software (v1.47v; National Institute of Health). For biochemical quantiﬁcation of
liver ﬁbrosis, hepatic hydroxyproline (HP) content was determined as described
previously [6].
Statistical analysis
Statistical analysis was performed using SPSS (Release 14.0, 2005, SPSS Inc., Chi-
cago, IL). For single time point comparison of two groups the Student’s t-test or,
where appropriate, the non-parametric Mann–Whitney U-test was used. The
number of animals per group was as follows: naive, n = 7; control, n = 7; UDCA,
n = 12; norUDCA, n = 14. A p value of less than 0.05 was considered signiﬁcant.
Additional Materials and methods are provided in the Supplementary mate-
rial section.Results
NorUDCA treatment improves liver histology and reduces granuloma
size in hepatic schistosomiasis without any antihelminthic effect
Infection with S. mansoni cercariae was uniformly accomplished
in all experimental groups, proven microscopically (by a board
certiﬁed expert pathologist, C.L.), by determination of granuloma
count/per low power ﬁeld (control: 7.6 ± 2.3; UDCA: 5.5 ± 1; nor-
UDCA: 6 ± 1.5) and via quantiﬁcation of antibodies against para-
site eggs (Fig. 1A and B). Morphometric analysis of liver slices5 vol. 62 j 871–878
Table 1. Serum liver biochemistry.
Conditions
Naive
(n = 7)
Control
(n = 7)
UDCA
(n = 12)
NorUDCA
(n = 14)
ALT (U/L) 75 ± 66 78 ± 28 101 ± 23 108 ± 44
AP (U/L) 59 ± 12 53 ± 14 71 ± 19*# 78 ± 20*#
BA (µmol/L) 34 ± 12 28 ± 17 141 ± 64*# 287 ± 32*#†
Serum biochemistry of naive mice (healthy; n = 7) vs. control (infected, untreated;
n = 7), UDCA (infected, UDCA-treated, n = 12) and norUDCA (infected, norUDCA-
treated, n = 14). Results are given as mean ± SD.
ALT, alanine aminotransferase; AP, alkaline phosphatase; BA, bile acids.
⁄p <0.05 (vs. naive), #p <0.05 (vs. control), p <0.05 (vs. UDCA).
JOURNAL OF HEPATOLOGYdemonstrated a signiﬁcant reduction (up to 50%) of the
granuloma size after norUDCA treatment, compared to UDCA
and control (% of control: UDCA, 98 and norUDCA, 51) (Fig. 1C).
Serum parameters for hepatocellular injury (ALT) remained
unchanged 16 weeks following infection, while bile acid feeding
resulted in signiﬁcantly higher levels of serum AP levels com-
pared to naive and control mice (Table 1). Notably, the local duc-
tular reaction (in response to granuloma formation), reﬂected by
keratin 19 (K19) staining, was enhanced after UDCA treatment
but attenuated after norUDCA treatment (Supplementary Fig. 1).
Furthermore, in vitro studies were designed to explore
potential direct antihelminthic effects of bile acids. All isolated
adult S. mansoni worms died within 6 h by control incubation* 
* * # 
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measured by ELISA. Both cytokines were signiﬁcantly elevated after S. mansoni infection.
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Journal of Hepatology 201with Praziquantel. Monitoring of bile acid treated groups over
5 days showed no antihelminthic effects of norUDCA or UDCA
(% of vital worms after 5 days of incubation: Praziquantel, 0; con-
trol, 95.8; UDCA, 93.3; norUDCA, 95.5).
UDCA and norUDCA treatment attenuates inﬂammatory reaction in
hepatic schistosomiasis
Immunohistochemical analysis of liver slices revealed a sub-
stantial accumulation of F4/80+ and CD11b+ monocytes/macro-
phages and granulocytes around tissue entrapped eggs, in
untreated controls compared to naive mice (Fig. 2A). Treat-
ment with both bile acids led to a signiﬁcant reduction of
F4/80+ (but not CD11b+) cells compared to the untreated con-
trol (Fig. 2B).
Serum levels of IL-1 beta and TNF-alpha were signiﬁcantly
increased 16 weeks following S. mansoni infection in control mice
compared to the naive group. Both bile acids signiﬁcantly antag-
onized this effect for IL-1 beta (Fig. 2C). This goes in line with
mRNA expression proﬁle of classical proinﬂammatory genes
(Supplementary Table 2). Both bile acids tended to reduce classi-
cal inﬂammation markers to similar degrees, although this was
not reﬂected by ﬁbrosis with UDCA. In addition, markers for
alternatively activated macrophages were assessed. Arg1 expres-
sion proﬁle displayed a signiﬁcant reduction following S. mansoni
infection (control) compared to naive mice, whereas UDCA and
norUDCA only tended to reduce Arg1. Notably, we observed a sig-* 
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Fig. 3. NorUDCA signiﬁcantly reduces hepatic ﬁbrosis in chronically infected Schistosoma mansoni mice. (A) Representative liver histology (Sirius Red staining, SR;
original magniﬁcation 100), of female NMRI mice 16 weeks after infection with 50 S. mansoni cercariae, receiving control diet and UDCA (0.5% wt/wt) or norUDCA (0.5%
wt/wt) enriched diet for 4 weeks, is shown (original magniﬁcation 100). Hepatic ﬁbrosis with pronounced expansion of connective tissue between hepatic granulomas
was most conspicuous in the control and UDCA group, and was reduced after norUDCA feeding. Immunohistochemistry for alpha-SMA (original magniﬁcation 200)
revealed a pronounced number of positive cells within ﬁbrotic areas and around egg granulomas in non-treated (control) and UDCA fed mice. Reduced numbers of alpha-
SMA+ cells under norUDCA treatment can be observed. (B) Representative Western blot for alpha-SMA and beta-actin (as loading control). (C) Fibrosis and alpha-SMA levels
were further analyzed by computerized quantiﬁcation of SR positive areas of liver sections, Western blot densitometry, and hydroxyproline measurements. (D) Serum levels
of proﬁbrotic TH2 cytokines IL-13 and IL-4 were measured by ELISA. Both cytokines were signiﬁcantly elevated 16 weeks following S. mansoni infection. NorUDCA (but not
UDCA) feeding for 4 weeks resulted in a signiﬁcant reduction of IL-13 and IL-4 serum level. Protein values were calculated by standard curve concentrations of recombinant
IL-13 and IL-4. Protein concentrations were expressed as means ± SD of duplicates. ⁄p <0.05 (vs. naive), #p <0.05 (vs. control), p <0.05 (vs. UDCA).
Research Articleniﬁcant reduction of Retnla expression after norUDCA treatment
comparable to Retnla levels of naive mice. Both bile acids exert
similar effects on classical proinﬂammatory genes whereas only
norUDCA affected alternatively activated macrophages in case
of Retnla. Moreover, norUDCA (but not UDCA) reduced interleu-
kin (IL)-13 and -4 serum levels (Fig. 3D).
NorUDCA signiﬁcantly reduces liver ﬁbrosis in hepatic schistosomiasis
SR-stained liver slices of control and UDCA-treated mice
showed expanding ﬁbrosis with pronounced portal-portal
bridging that was signiﬁcantly reduced in response to norUDCA
treatment (Fig. 3A). This was supported by a reduction of
alpha-SMA+ cells on liver slices (Fig. 3A) and reduced alpha-
SMA protein levels (Fig. 3B) as well as hepatic hydroxyproline
(HP) levels, as markers for biochemical quantiﬁcation of liver
ﬁbrosis by norUDCA (Fig. 3C). IL-13 and -4 serum protein levels
were determined since these cytokines have a regulatory
importance in TH2 driven liver ﬁbrosis. Serum levels of both
proﬁbrotic cytokines were signiﬁcantly reduced after norUDCA
treatment compared to the control and UDCA groups
(Fig. 3D). In addition, as shown in Supplementary Table 2,
norUDCA reduced TGF-beta expression. Interestingly, infected
mice displayed a characteristic increase of matrix metallopro-
teinase-2 (MMP-2) and tissue inhibitor of metalloproteinase
(TIMP-1) mRNA expression levels, which was reduced by both
bile acids treatments (Supplementary Table 2). Notably, the
TIMP-1 to MMP-2 ratio was reduced only by norUDCA (but
not UDCA), which may reﬂect a beneﬁcial shift favouring
matrix degradation (Supplementary Table 3).874 Journal of Hepatology 201Taken together, these data indicate that norUDCA diminished
development and ameliorated parameters of hepatic ﬁbrosis,
whereas UDCA had no effect on liver ﬁbrosis, in this model
system.
NorUDCA treatment reduces content of inﬂammatory cell inﬁltrate
and changes cell composition of hepatic S. mansoni granulomas
Since norUDCA treatment resulted in signiﬁcantly reduced gran-
uloma size, immunohistochemistry was performed to analyze
potential changes in cell composition of hepatic S. mansoni gran-
ulomas after bile acid treatment. Cell numbers of macrophages
(F4/80), T-lymphocytes (CD3), neutrophils (MPO), and eosino-
phils (HE-staining) were determined microscopically, by count-
ing positive cells in 20 hepatic granulomas per liver slide of
each mouse. In norUDCA treated mice, all analyzed cell types
were signiﬁcantly reduced compared to untreated control and
UDCA. In addition, the relative cellular composition of inﬂamma-
tory cells within hepatic granulomas of this group was changed
with a signiﬁcant reduction of CD3+ T-lymphocytes. IHC for Ki-
67 revealed reduced cell proliferation within hepatic granulomas
of norUDCA treated mice (Fig. 4A and B).
NorUDCA impairs surface expression of major histocompatibility
complex (MHC) class II of antigen presenting cells and blocks T-cell-
receptor dependent and independent activation/proliferation without
inducing apoptosis
Populations of double positive bone marrow derived macro-
phages (BMDM: F4/80+/MHC II+) and dendritic cells (BMDC:5 vol. 62 j 871–878
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Fig. 4. NorUDCA treatment reduces content of inﬂammatory cell inﬁltrate and changes cell composition of hepatic Schistosoma mansoni granulomas.
Immunohistochemistry on liver slices was performed to characterize cell composition of hepatic S. mansoni granulomas with or without bile acid treatment. (A)
Representative images for H&E (eosinophils, original magniﬁcation 630), CD3 (T-lymphocytes, original magniﬁcation 400), F4/80 (macrophages, original magniﬁcation
200), and MPO (neutrophils, original magniﬁcation 400) are shown. IHC for Ki-67 (cellular proliferation, original magniﬁcation 100) revealed a signiﬁcant reduction of
dividing cell activity within the norUDCA group compared to UDCA and control. Respective cell numbers were determined microscopically by counting positive cells in 20
hepatic granulomas (hg) per liver slide of each mouse (control: n(hg) = 140; UDCA: n(hg) = 240; norUDCA: n(hg) = 280). Schistosomal hemozoin pigment (brownish
pigment) within portal tract and parenchymal interface can be observed. (B) Quantiﬁcation of cell populations within hepatic granulomas revealed a signiﬁcant change in
cell composition towards a lower content of CD3+ T-lymphocytes. #p <0.05 (vs. control), p <0.05 (vs. UDCA).
JOURNAL OF HEPATOLOGYCD11c+/MHC II+) were analyzed by ﬂow cytometry. Comparable
amounts of double positive BMDMs were generated in control
and UDCA-treated cells, whereas norUDCA signiﬁcantly reduced
the amount of double positive BMDMs (Fig. 5A). The same pat-
tern was observed in BMDCs. Only half of CD11c+ cells present
an MHC II signal on their surface. This was also reﬂected by
signiﬁcantly reduced CIITA expression levels in BMDMs, after
norUDCA incubation (Fig. 5A).
CD3/CD28 activation of CD4+ primary mouse T-lymphocytes
led to a strong proliferation in controls and UDCA-treated cells,
demonstrated by BrdU incorporation, while norUDCA com-
pletely repressed proliferation of CD3/CD28 (receptor depen-
dent) as well as PMA/ionomycin (receptor independent)
activated CD4+ T-lymphocytes (Fig. 5B). This has been veriﬁed
by reduced intracellular CFSE concentration due to cell division
activity (Supplementary Fig. 2). Moreover, norUDCA treated
T-lymphocytes did not enter interphase of cell cycle compared
to control and UDCA (Fig. 5B). To investigate potential
apoptotic effects of norUDCA, annexin-V/7-AAD staining was
performed. Neither UDCA nor norUDCA induced programmed
cell death (Fig. 5C).
Taken together, these data indicate that norUDCA, in contrast
to UDCA, directly impairs antigen presentation of APCs, by CIITAJournal of Hepatology 201regulated suppression of MHC II expression [20] in vitro, and fur-
ther indicate anti-proliferative properties of norUDCA in regard to
inhibited activation (proliferation) of T-lymphocytes.Discussion
This study aimed at investigating the therapeutic properties and
potential direct anti-inﬂammatory and anti-ﬁbrotic mechanisms
of the novel bile acid norUDCA, in an inﬂammation-mediated
model of liver ﬁbrosis without cholestasis [21]. We have chosen
its chemical mother compound UDCA as a clinical comparator.
Previous experiments, using cholestatic Abcb4/ mice with
sclerosing cholangitis and biliary type of liver ﬁbrosis, have dem-
onstrated anti-ﬁbrotic effects of norUDCA [6] and, to a lesser
degree, UDCA; the latter even aggravated liver injury at high
doses [22]. Since both drugs are anti-cholestatic and previously
observed anti-ﬁbrotic effects may at least in part be related to
these mechanisms, we searched for an alternative – preferentially
non-cholestatic – model for liver ﬁbrosis, to further discriminate
the differential effects of both interesting therapeutic bile acids. S.
mansoni infected NMRI mice develop a robust and sustained
hepatic ﬁbrosis without signiﬁcantly elevated serum parameters5 vol. 62 j 871–878 875
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and dendritic cells (BMDC) and inhibits proliferation of primary CD4+ T-lymphocytes. (A) Haematopoietic stem cells of uninfected female NMRI mice were incubated
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for BMDMs (F4/80) and BMDCs (CD11c). mRNA expression level of the key MHC class II regulator CIITA was signiﬁcantly downregulated after norUDCA incubation, in
contrast to UDCA and control. (B) CD4+ T-lymphocytes, isolated from chronically S. mansoni infected NMRI mice, were stimulated with CD3/CD28 dynabeads. NorUDCA
signiﬁcantly inhibited proliferation of T-lymphocytes, conﬁrmed by BrdU incorporation. Stimulated, norUDCA incubated T-lymphocytes did not enter cell cycle interphase
(propidium iodide staining); whereas control and UDCA treated cells started to proliferate following stimulation. (C) T-lymphocytes from mesenteric lymph nodes of S.
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not induce apoptosis. For validation of the method and reproducibility of the results, the experiments were repeated in two independent series. ⁄p <0.05 (vs. unstimulated
control), #p <0.05 (vs. control), p <0.05 (vs. UDCA).
Research Articlefor hepatocellular injury [21]. Proliferation of bile ducts was
observed in areas of hepatic granulomas, while ‘‘granuloma free’’
area was completely unremarkable. Notably, the local ductular
reaction in response to granulomas was even enhanced after
UDCA treatment but declined after norUDCA treatment. In areas
of hepatic granulomas, where pre-existing bile ducts may be
compressed, choleretic UDCA could provoke a local aggravation
of the biliary reaction, as observed under more pronounced
cholestatic conditions (e.g., Abcb4/Mdr2/ mice and bile duct
ligation), by enhancing biliary pressure and subsequent bile
infarcts while norUDCA was beneﬁcial [22,23]. However, in the
current S. mansoni mouse model, UDCA did not aggravate hepatic
injury or inﬂammation compared to untreated control, as
reﬂected by unchanged ALT levels and even improved inﬂamma-
tory markers. Although, norUDCA is also a potent choleretic, the
associated induction of bicarbonate rich choleresis as a result of
cholehepatic shunting [23], and its antiproliferative properties
[24], may explain its beneﬁcial effects on ductular reaction. In
this regard, it is also important to note that elevated serum bile
acid levels, as observed in the current study in norUDCA-fed S.
mansoni-infected mice, may be attributed to the high bioavail-
ability of cholehepatic-shunting norUDCA, rather than reﬂecting
a cholestatic condition. This is related to the relative conjugation
resistance of norUDCA [13,15]. As such, the reabsorption of
secreted norUDCA by cholangiocytes leads to high serum and876 Journal of Hepatology 201intrahepatic norUDCA concentrations [6,25]. As a possible conse-
quence, the observed beneﬁcial anti-ﬁbrotic and anti-inﬂamma-
tory effects of norUDCA in vivo could, at least in part, be related
to direct antihelminthic actions of norUDCA. However, the reduc-
tion of granuloma size in the presence of unchanged absolute
granuloma numbers and unchanged survival of isolated worms
and eggs in vitro argues against this interesting option.
The severity of S. mansoni pathology depends at least on the
balance of TH1 and TH2 mediated responses, and is mostly
related to a dysbalance of matrix degradation and its inhibition
[26]. Herein we demonstrate a signiﬁcantly shifted ratio of
MMP-2 and TIMP-1 towards MMP-2 after norUDCA treatment,
and markedly reduced inﬂammatory response in S. mansoni
infected mice, after UDCA and norUDCA feeding. However, only
norUDCA treatment led to a reduced granuloma size with second-
ary beneﬁcial effects on TH2-cytokine (IL-13 and -4) driven hepa-
tic ﬁbrosis. In hepatic schistosomiasis, inﬂammation (TH1) and
ﬁbrosis (TH2) are differentially regulated since it is known that
IL-13 affects ﬁbrosis directly in a TGF-beta independent manner
[27], and IL-13/ mice failed to develop an adequate ﬁbrotic
response to S. mansoni egg antigens [28]. In our study, we demon-
strated comparable effects of UDCA and norUDCA on proinﬂam-
matory cytokines, but without any beneﬁcial effects on hepatic
ﬁbrosis in UDCA treated mice, possibly indicating a minor rele-
vance of these markers for S. mansoni related disease progression.5 vol. 62 j 871–878
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The speciﬁc anti-ﬁbrotic effect of norUDCA in this model may be
linked to mechanisms directed against TH2 response. This con-
cept is further supported by norUDCA effect on Retnla, presenting
a marker for alternatively activated macrophages and negative
regulator of TH2-response [29,30]. Notably, we observed a signif-
icant reduction of Retnla expression after norUDCA treatment,
comparable to Retnla levels of naive mice. Unfortunately, little
is known about Retnla function in TH2 immunity and affected
cell types, but its regulation is controlled by IL-4/IL-13 and STAT6
[31,32]. We demonstrated reduced serum levels of both TH2
cytokines (IL-13 and -4) accompanied by reduced numbers of
CD3+ and Ki-67+ cells in granulomas of the norUDCA (but not
UDCA) group. The relevance of local expansion of activated T-
lymphocytes for granuloma formation and controlling of inﬂam-
matory processes is still unclear [33]. However, our analysis
revealed a signiﬁcantly changed percentage distribution of cellu-
lar composition of hepatic granulomas after norUDCA treatment
accompanied by reduced granuloma size, declined formation of
ﬁbrotic septa, and reduced hepatic ﬁbrosis. In addition, we could
demonstrate a reduction of Ki-67+ cells at the edges of granulo-
mas, where CD3+ cells are located; suggesting that local prolifer-
ation of T-lymphocytes may be restrained after norUDCA
treatment. This is in line with our in vitro settings of restimulated
T-lymphocytes with anti-CD3/CD28 coupled beads and receptor
independent stimulation with PMA/Ionomycin that was com-
pletely detained after norUDCA incubation without inducing
apoptosis in these cells.
In addition, a strongly reduced expression of MHC II mole-
cules on BMDMs as well as BMDCs after incubation with
norUDCA could in turn provide an explanation for a reduced anti-
gen presentation and subsequent T-cell activation observed with
norUDCA. Noteworthy, in our setting UDCA did not show any
effects on maturation of APCs and MHC II expression. However,
UDCA is able to directly reduce MHC II expression on biliary
epithelium and hepatocytes by activating the glucocorticoid
receptor, followed by an inhibited IFN-c-mediated MHC II activa-
tion [34]. Together with our observation on alternatively acti-
vated macrophages, we suggest that the UDCA effect might be
restricted to the classical activation cascade of macrophages
and is lost upon alternatively IL-4/IL-13 activated macrophages,
within a TH2 milieu [35,36]. Further characterization of the
APC/T-cell interplay is clearly required to obtain additional
insights into the anti-inﬂammatory and immune modulatory
mechanisms of norUDCA activity and the interactions with the
complex inﬂammation process of S. mansoni infection.
In summary, this study demonstrates: (i) beneﬁcial effects of
norUDCA on granuloma size and hepatic ﬁbrosis, (ii) anti-inﬂam-
matory properties of norUDCA directed to MHC class II protein
expression on dendritic cells and macrophages, and (iii) direct
anti-ﬁbrotic effects of norUDCA by reduced T-lymphocyte prolif-
eration and ﬁnally reduced serum levels of IL-13 and IL-4. This
potentiality may qualify norUDCA as a promising drug for non-
cholestatic, inﬂammation-driven liver ﬁbrosis.Financial support
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